Roth Mkm Reiterates “Buy” Rating for Nuwellis (NASDAQ:NUWE)

Nuwellis (NASDAQ:NUWE)‘s stock had its “buy” rating restated by investment analysts at Roth Mkm in a note issued to investors on Tuesday, Benzinga reports. They presently have a $17.00 price target on the stock.

Separately, Roth Capital raised shares of Nuwellis to a “strong-buy” rating in a research report on Monday, July 29th.

Nuwellis Trading Down 23.0 %

NASDAQ NUWE traded down $0.61 during trading hours on Tuesday, reaching $2.04. The company had a trading volume of 644,028 shares, compared to its average volume of 226,996. The stock has a 50-day moving average of $4.80 and a 200 day moving average of $10.46. Nuwellis has a 1-year low of $2.00 and a 1-year high of $92.75. The stock has a market capitalization of $1.33 million, a P/E ratio of -0.01 and a beta of 0.44.

Nuwellis Company Profile

Nuwellis, Inc, a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics.